DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with several local companies and attended events. The first of this series was a conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. Here, DDW summarises what was learnt about… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Thijs Spoor, CEO… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Thijs Spoor, CEO… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More
The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The findings, published in a series of papers in Nature Medicine, reveal… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “… Read More
One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding… Read More
Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, has published a study in Cell, introducing its optogenetic screening platform. According to the paper, the platform allows for precise and dynamic control of biological targets and processes, unlocking a powerful new… Read More
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding (MoU) to jointly advance the industrialisation and scale-up of Sensible’s first-in-class cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the “next… Read More
Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread through the body. A team of researchers from The Institute of Cancer Research, London, has identified that a… Read More
FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More
The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More
The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More
The International Society for Cell & Gene Therapy (ISCT)’s conference took place from 7-10 May, just before the American Society of Gene & Cell Therapy (ASGCT)’s conference from 13-17 May, both in New Orleans. Here, industry experts provided DDW’s Megan Thomas with insight from the events. Allogeneic cell therapies Lindsay… Read More
